Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma

Mdm2 Deficiency Suppresses MYCN-Driven Neuroblastoma Tumorigenesis In Vivo

(2015) Zaowen Chen et al.   NEOPLASIA

Current strategies to target p53 in cancer

(2010) Fang Chen et al.   BIOCHEMICAL PHARMACOLOGY

MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia

(2010) Kerstin Willander et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Improved Survival of Children With Neuroblastoma Between 1979 and 2005: A Report of the Italian Neuroblastoma Registry

(2010) Riccardo Haupt et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation

(2010) Adrianne L. Myers et al.   JOURNAL OF PEDIATRIC SURGERY

Associations of MDM2 SNP309, Transcriptional Activity, mRNA Expression, and Survival in Stage I Non-Small-Cell Lung Cancer Patients with Wild-Type p53 Tumors

(2009) Wen-Pin Chien et al.   ANNALS OF SURGICAL ONCOLOGY

Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1α

(2009) Yoon-Mi Lee et al.   CARCINOGENESIS

Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

(2009) Katherine K. Matthay et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53

(2009) Tom Van Maerken et al.   JNCI-Journal of the National Cancer Institute

Targeted Molecular Therapy for Neuroblastoma: The ARF/MDM2/p53 Axis

(2009) Eugene Kim et al.   JNCI-Journal of the National Cancer Institute

Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma

(2009) Brian H. Kushner et al.   PEDIATRIC BLOOD & CANCER

MDM2SNP309 genotype influences survival of metastatic but not of localized neuroblastoma

(2009) Chiara Perfumo et al.   PEDIATRIC BLOOD & CANCER

Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study

(2008) Julia L. Glade Bender et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of HDM2 as a regulator of VEGF expression in cancer cells

(2008) Madhusudhanan Narasimhan et al.   LIFE SCIENCES